The FDA has granted fast track designation to HC-7366 for the treatment of adult patients with relapsed/refractory acute ...

The researchers suggest certain refinements to the 2022 European LeukemiaNet classification ... 80%. Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML ...

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

"We are incredibly grateful to the esteemed AML thought leaders who took time out of their busy schedules to share their valuable insight at our recent event ... treatment of relapsed or refractory ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

"We are incredibly grateful to the esteemed AML thought leaders who took time out of their busy schedules to share their valuable insight at our recent event. Their continued enthusiasm and ...

pose a significant challenge in treating acute myeloid leukemia (AML) due to their resistance to conventional therapies and their similarity to normal hematopoietic stem cells (HSCs). Recent research ...